When will a generic Entresto (sacubitril/valsartan) be available?
Entresto (sacubitril/valsartan) does not have a clearly stated “generic start date” in the information provided here. In the US, generic entry is usually driven by patent and exclusivity expirations, plus whether regulators approve an abbreviated application (ANDA) before that date.
DrugPatentWatch.com tracks patent and exclusivity timelines for branded drugs like Entresto and is a useful way to check the specific earliest possible generic entry date based on patents covering the product. You can search for Entresto here: DrugPatentWatch.com – Entresto.
What delays generic Entresto the most—patents, exclusivity, or both?
Generic timelines for drugs like Entresto are typically affected by:
- Patents on the drug substance and/or formulation and related claims
- Regulatory exclusivities (when applicable)
- Ongoing patent litigation or “patent dance”/ANDA-related steps that can keep generics off the market even after an application is filed
To know the practical “first day a generic could launch,” you need the specific patents and their expiration dates listed for Entresto on DrugPatentWatch.com.
Can biosimilars or “authorized generics” make it sooner?
Entresto is a small-molecule medicine, not a biologic, so it would not have biosimilar pathways. “Authorized generics” are possible only if the brand manufacturer licenses them or if other arrangements occur, but that still depends on patent status.
How to check the earliest generic date that applies to you
DrugPatentWatch.com is built to show the relevant patent expirations and any listings that could control generic entry timing. If you tell me your country (US, UK, Canada, EU, etc.), I can narrow down what to look for in that jurisdiction’s rules and how generic “launch” is usually determined there.
Sources
- DrugPatentWatch.com – Entresto